The MMRC is not only the first collaborative research organization of its kind, it is dedicated to advancing innovative Phase 1 and Phase 2 clinical trials of today’s most promising drug candidates.
The MMRC has conducted 76 clinical trials, 24 of which are currently ongoing. Below are highlights and information about three of these exciting trials:
CLINICAL TRIAL ID: NCT03252600
Revlimid®/Dexamethasone/ Empliciti™ for Patients with Relapsed AL Amyloidosis
Patients with relapsed primary amyloidosis who have received one line of prior therapy.
Amyloidosis is a serious complication of multiple myeloma that affects up to 30% of myeloma patients at some point. This year, the MMRC has added an amyloidosis trial to their trial lineup for the first time ever!
This trial is studying how well lenalidomide, dexamethasone, and Empliciti with or without Cytoxan work in treating patients with primary amyloidosis that has come back after a period of improvement. These are chemotherapy drugs that work in different ways to stop the growth of cancer cells by killing them or stopping them from dividing or spreading.
Empliciti is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide, dexamethasone, and Empliciti with Cytoxan may work better in treating patients with a relapse of primary amyloidosis.
CLINICAL TRIAL ID: NCT03091257
Tafinlar and/or Mekinist in Patients with Relapsed and/or Refractory Multiple Myeloma and BRAF/NRAS/ KRAS Mutations
Patients with confirmed mutations in the BRAF, NRAS, or KRAS genes.
This pilot is evaluating two drugs for the first time in myeloma. Patients with multiple myeloma whose tumors have a mutation in the BRAF, NRAS, or KRAS genes will be given one of three treatments – dabrafenib plus trametinib, dabrafenib alone, or trametinib alone.
These mutations were first documented in multiple myeloma through research done by the MMRF in our MMGI and CoMMpass studies. Dabrafenib and trametinib work to block the BRAF, NRAS, and KRAS mutant genes from contributing to the spread of myeloma.
These drugs have already been approved for treatment of other BRAF/RAS mutant cancers, such as melanoma, which suggests that these agents may help to kill mutant multiple myeloma cells. This is the second MMRC trial (the first was the MDM2 trial) to offer a precision treatment to patients based on their DNA sequencing results.
CLINICAL TRIAL ID: NCT02952573
FGFR3 Inhibitor JNJ-42756493 with Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Patients who have had at least one prior line of treatment and have a documented FGFR3 status.
This study aims to determine how effective investigational drug JNJ-42756493 is when given together with dexamethasone.
The study is looking at two groups of patients: The first group have tumors with a mutation in a gene called Fibroblast Growth Factor Receptor-3 (FGFR3), which may be involved in the growth of myeloma. The second group of patients has tumors containing a normal FGFR3 gene. JNJ-42756493 has shown effectiveness against tumors with mutant FGFR3 and may boost the effectiveness of dexamethasone for these patients.
The existence of FGFR3 mutations in myeloma was confirmed in our CoMMpass Study. This is the third precision medicine treatment that has advanced into an MMRC clinical trial for myeloma patients as a result of genomic data generated by the MMRF.
Interested in participating in clinical trials? Talk to an MMRF Patient Support Nurse at 1-866-603MMCT(6628) or use our Clinical Trials Finder.